Methods of diagnosis and prognosis of ovarian cancer II
OwnerPhilippa O'Brien, Robert Sutherland +1inventors
InventorsPhilippa O'Brien, Robert Sutherland, Susan Henshall
Life of this patent
Estimating the term…
Abstract
The present invention provides novel genes and proteins for diagnosing ovarian cancer and/or a likelihood for survival, or recurrence of disease, wherein the expresson of the genes and proteins is up-regulated or down-regulated or associated with the occurrence or recurrence of a specific cancer sub-type. The ovarian cancer-associated genes and proteins of the invention are specifically exemplified by the genes and proteins set forth in Tables 1 to 5 and the Sequence Listing.
Claims26
1-6. (canceled)
A method of diagnosing an ovarian cancer in a human or animal subject being tested said method comprising contacting a biological sample from said subject being tested with a nucleic acid probe for a time and under conditions sufficient for hybridization to occur and then detecting the hybridization wherein a reduced level of hybridization of the probe for the subject being tested compared to the hybridization obtained for a control subject not having ovarian cancer indicates that the subject being tested has an ovarian cancer, and wherein said nucleic acid probe comprises a sequence selected from the group consisting of:
- (i) a sequence comprising at least about 20 contiguous nucleotides from the nucleotide sequence of a gene set forth in Table 2 or mixtures thereof;
- (ii) a sequence that hybridizes under at least low stringency hybridization conditions to at least about 20 contiguous nucleotides from the nucleotide sequence of a gene set forth in Table 2 or mixtures thereof;
- (iii) a sequence that is at least about 80% identical to (i) or (ii);
- (iv) a sequence that encodes a polypeptide encoded by the nucleotide sequence of a gene set forth in Table 2 or mixtures thereof;
- and
- (v) a sequence that is complementary to any one of the sequences set forth in (i) or (ii) or (iii) or (iv).
(canceled)
15-18. (canceled)
A method of diagnosing an ovarian cancer in a human or animal subject being tested said method comprising contacting a biological sample from said subject being tested with an antibody for a time and under conditions sufficient for an antigen-antibody complex to form and then detecting the complex wherein a reduced level of the antigen-antibody complex for the subject being tested compared to the amount of the antigen-antibody complex formed for a control subject not having ovarian cancer indicates that the subject being tested has an ovarian cancer, and wherein said antibody binds to a polypeptide comprising an amino acid sequence comprising at least about 10 contiguous amino acid residues of a polypeptide encoded by a gene set forth in Table 2 or mixtures thereof.
24-69. (canceled)
A method of diagnosing an ovarian cancer in a human or animal subject being tested said method comprising determining aberrant methylation in the promoter sequence of a gene in a biological sample from said subject compared to the methylation of the promoter in nucleic acid obtained for a control subject not having ovarian cancer wherein said aberrant methylation indicates that the subject being tested has an ovarian cancer and wherein the gene comprises a sequence selected from the group consisting of:
- (i) the nucleotide sequence of a gene set forth in Table 2 or mixtures thereof;
- (ii) a sequence that hybridizes under at least low stringency hybridization conditions to the nucleotide sequence of a gene set forth in Table 2 or mixtures thereof;
- (iii) a sequence that is at least about 80% identical to (i) or (ii);
- (iv) a sequence that encodes a polypeptide encoded by a gene set forth in Table 2 or mixtures thereof;
- and
- (v) a sequence that is complementary to any one of the sequences set forth in (i) or (ii) or (iii) or (iv).
(canceled)
(canceled)
Dependencies are inferred from the claim text.